OPTIRAY 240 Drug Patent Profile

Which patents cover Optiray 240, and what generic alternatives are available?

Optiray 240 is a drug marketed by Liebel-flarsheim and is included in two NDAs.

The generic ingredient in OPTIRAY 240 is ioversol. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ioversol profile page.

Summary for OPTIRAY 240

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	3
Patent Applications:	1,980
DailyMed Link:	OPTIRAY 240 at DailyMed

Recent Clinical Trials for OPTIRAY 240

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GE Healthcare	Phase 4
Bayer	Phase 4
Guerbet/Liebel-Flarsheim	Phase 4

See all OPTIRAY 240 clinical trials

Pharmacology for OPTIRAY 240

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

US Patents and Regulatory Information for OPTIRAY 240

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Liebel-flarsheim	OPTIRAY 240	ioversol	INJECTABLE;INJECTION	019710-002	Dec 30, 1988		DISCN	Yes	No
Liebel-flarsheim	OPTIRAY 240	ioversol	INJECTABLE;INJECTION	020923-001	May 28, 1998		DISCN	No	No

Expired US Patents for OPTIRAY 240

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Liebel-flarsheim	OPTIRAY 240	ioversol	INJECTABLE;INJECTION	019710-002	Dec 30, 1988
Liebel-flarsheim	OPTIRAY 240	ioversol	INJECTABLE;INJECTION	020923-001	May 28, 1998

International Patents for OPTIRAY 240

See the table below for patents covering OPTIRAY 240 around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	3362967
European Patent Office	0083964	COMPOUNDS SUITABLE FOR X-RAY VISUALISATION METHODS
Australia	552188
Japan	H0224252
Netherlands	930067
Canada	1198739	DERIVES DE 2,4,6-TRIIODOISOPHTALAMIDE (2,4,6-TRIIODOISOPHTHALAMIDE DERIVATIVE)
Japan	S58131970	COMPOUND

Supplementary Protection Certificates for OPTIRAY 240

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0083964	SPC/GB93/089	United Kingdom		SPC/GB93/089: 20041015
0083964	93C0142	Belgium		PRODUCT NAME: IOVERSOL; NAT. REGISTRATION NO/DATE: 74 IS 56 F12/19910521; FIRST REGISTRATION: NL RVG 13345 19891016

OPTIRAY 240 Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for OPTIRAY 240

Introduction to OPTIRAY 240

OPTIRAY 240, a nonionic iodinated radiographic contrast medium, is a formulation of ioversol, commonly used in various medical imaging procedures. It is indicated for cerebral angiography, venography, excretory urography, and contrast-enhanced computed tomographic imaging of the head and body[2][3][5].

Market Size and Growth

The global ioversol market, which includes OPTIRAY 240, has shown significant growth in recent years. As of 2023, the global ioversol market size was valued at approximately $0.49 billion. This market is projected to grow to $0.86 billion by 2031, with a compound annual growth rate (CAGR) of 7.22% during the forecast period from 2023 to 2031[4].

Segmentation and Market Share

OPTIRAY 240 is part of the broader ioversol market, which is segmented by type and application. The types of ioversol solutions include:

• Ioversol 34% Injectable Solution (Optiray 160)
• Ioversol 51% Injectable Solution (Optiray 240)
• Ioversol 64% Injectable Solution (Optiray 300)
• Ioversol 68% Injectable Solution (Optiray 320)
• Ioversol 74% Injectable Solution (Optiray 350)[1][4].

OPTIRAY 240, specifically, holds a significant share within the ioversol market due to its versatile applications in cerebral angiography, venography, and CT scans. It is one of the most commonly used concentrations for these procedures[2][3].

Regional Analysis

The market for OPTIRAY 240 is distributed across various regions, including North America, Europe, Asia Pacific, South America, and the Middle East and Africa. North America and Europe are among the leading regions due to advanced healthcare infrastructure and higher adoption rates of diagnostic imaging technologies.

• North America: This region is expected to dominate the market due to the high prevalence of cardiovascular and neurological disorders, which require frequent use of contrast agents like OPTIRAY 240[4].
• Europe: Europe also holds a substantial market share, driven by the presence of well-established healthcare systems and a high demand for diagnostic imaging procedures[4].

Competitive Landscape

The market for ioversol, including OPTIRAY 240, is competitive with several key players:

• Liebel Flarsheim Company LLC
• Guerbet
• Jiangsu Hengrui Medicine Co
• Mallinckrodt Pharmaceuticals
• Ultraject
• China Resources Pharmaceutical (Shanghai) Co
• HB Ocean
• Novalek Pharmaceuticals Pvt. Ltd
• Stellence Pharmscience Pvt. Ltd
• A.S. Joshi & Company[1].

These companies compete based on product quality, pricing, and market penetration, with Liebel Flarsheim Company LLC being a notable player due to its association with the OPTIRAY brand.

Applications and Indications

OPTIRAY 240 is indicated for several critical medical imaging procedures:

• Cerebral Angiography: Used to visualize the blood vessels in the brain.
• Venography: Used to visualize the veins.
• Excretory Urography: Used to visualize the urinary tract.
• Computed Tomography (CT) Imaging: Used for contrast-enhanced imaging of the head and body[2][3][5].

These diverse applications contribute significantly to the market demand for OPTIRAY 240.

Market Drivers

Several factors drive the growth of the OPTIRAY 240 market:

• Increasing Prevalence of Chronic Diseases: The rising incidence of cardiovascular and neurological disorders necessitates more frequent use of diagnostic imaging procedures, thereby increasing the demand for contrast agents like OPTIRAY 240.
• Advancements in Diagnostic Imaging Technologies: Improvements in CT scan and angiography technologies enhance the accuracy and safety of procedures, leading to higher adoption rates.
• Growing Healthcare Expenditure: Increased spending on healthcare globally, especially in developed regions, supports the growth of the ioversol market[4].

Market Restraints

Despite the growth drivers, there are several restraints to consider:

• Adverse Reactions: Serious adverse reactions, such as severe hypersensitivity, cardiac issues, and renal impairment, can limit the use of OPTIRAY 240 in certain patient populations[2][3].
• Regulatory Scrutiny: Strict regulatory guidelines and the need for careful evaluation of risks versus benefits can slow market growth.
• Cost and Accessibility: High costs associated with diagnostic imaging procedures and the contrast agents themselves can be a barrier in some regions[3].

Financial Trajectory

The financial trajectory of OPTIRAY 240 is closely tied to the overall ioversol market. Here are some key financial metrics:

• Revenue Growth: The market is expected to grow from $0.49 billion in 2023 to $0.86 billion by 2031, indicating a robust financial trajectory[4].
• CAGR: A CAGR of 7.22% from 2023 to 2031 reflects a steady and significant growth rate.
• Regional Revenue: North America and Europe are expected to contribute substantially to the revenue, driven by their advanced healthcare systems and high demand for diagnostic imaging[4].

SWOT Analysis

Strengths

• Versatile Applications: OPTIRAY 240 is used in a variety of critical diagnostic procedures.
• Established Brand: Associated with Liebel Flarsheim Company LLC, a reputable player in the market.
• Wide Distribution: Available across multiple regions, including North America, Europe, and Asia Pacific.

Weaknesses

• Adverse Reactions: Potential for severe adverse reactions limits its use in certain patients.
• High Cost: The cost of the drug and associated procedures can be a barrier.

Opportunities

• Growing Demand for Diagnostic Imaging: Increasing prevalence of chronic diseases and advancements in imaging technologies.
• Expanding into New Markets: Potential for growth in emerging economies with improving healthcare infrastructure.

Threats

• Regulatory Changes: Strict regulations and potential changes in regulatory environments.
• Competitive Landscape: Presence of other contrast agents and competitive pricing strategies by rivals.

Key Takeaways

• The global ioversol market, including OPTIRAY 240, is projected to grow significantly from 2023 to 2031.
• OPTIRAY 240 has diverse applications in cerebral angiography, venography, and CT scans.
• The market is driven by increasing chronic disease prevalence and advancements in diagnostic imaging technologies.
• Despite growth drivers, the market faces restraints such as adverse reactions and regulatory scrutiny.
• The financial trajectory indicates robust revenue growth with a CAGR of 7.22%.

Frequently Asked Questions (FAQs)

Q: What are the primary indications for OPTIRAY 240? A: OPTIRAY 240 is indicated for cerebral angiography, venography, excretory urography, and contrast-enhanced computed tomographic imaging of the head and body[2][3][5].

Q: Which regions dominate the market for OPTIRAY 240? A: North America and Europe are the leading regions due to their advanced healthcare infrastructure and high demand for diagnostic imaging procedures[4].

Q: What are the potential adverse reactions associated with OPTIRAY 240? A: Serious adverse reactions include severe hypersensitivity, cardiac issues, renal impairment, and other systemic reactions[2][3].

Q: How is the market for OPTIRAY 240 expected to grow in the future? A: The market is expected to grow from $0.49 billion in 2023 to $0.86 billion by 2031, with a CAGR of 7.22%[4].

Q: Who are the key players in the ioversol market, including OPTIRAY 240? A: Key players include Liebel Flarsheim Company LLC, Guerbet, Jiangsu Hengrui Medicine Co, and others[1].

Cited Sources

1. Cognitivemarketresearch.com: Global Ioversol Market Report 2024 Edition.
2. NCBI: 320 Optiray® Pharmacy Bulk Package.
3. Health Canada: OPTIRAY Product Monograph.
4. FutureWise Research: Ioversol Market Overview.
5. FDA: FULL PRESCRIBING INFORMATION - Optiray.